Altasciences At CPHI Americas 2025

In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster. In May 2025, Altasciences attended CPHI Americas in Philadelphia, where industry leaders, innovators, and stakeholders gathered to explore the latest advancements in pharmaceutical development technologies and connect with providers. It was great to speak with our current clients and establish new contacts, and our participation not only highlighted Altasciences’ commitment to advancing drug development but also provided a unique platform to showcase our latest offering.

It was also great to represent Altasciences as both a CRO and a CDMO. With our presence at the event, we could showcase our core capabilities in drug development and manufacturing, as well as highlight our expanded portfolio of curated services.

Attendees were particularly drawn to our integrated solutions, which encompass everything from lead candidates advancing to IND-enabling programs to early-phase clinical trials to full-scale commercial manufacturing. Our unique model is designed to accelerate client timelines and positions us as a leader in the early-development CRO/CDMO space, and reinforces our dedication to supporting clients at every stage of their product lifecycle.
 

SOLVING PHARMACEUTICAL FORMULATION CHALLENGES WITH SPRAY DRYING TECHNOLOGY

At this year’s CPHI Americas, we had the chance to take the stage at the Innovation Theater and address one of the biggest hurdles in drug development: poor solubility and bioavailability of active pharmaceutical ingredients (APIs). It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve.

Our presentation highlighted spray drying, a powerful technique that can turn liquid formulations into fine powders. Why does that matter? Because this transformation can significantly improve the stability, solubility, and overall performance of pharmaceutical compounds, especially when it comes to small molecules.

Beyond the science, what’s exciting is how this technology opens doors. Better bioavailability means better outcomes, and potentially, faster paths through development. At Altasciences, we’ve built our capabilities to handle a wide range of formulations, liquid or solid, with the flexibility needed to support evolving drug development goals.

We enjoyed connecting with so many forward-thinking minds at CPHI and sharing how this kind of innovation is shaping the future of formulation science.
 

BIG IDEAS AND BRIGHT CONVERSATIONS ABOUT DRUG DEVELOPMENT

The CPHI Innovation Theater was buzzing with energy—and Altasciences was right in the mix. It was the perfect venue for meaningful conversations with pharmaceutical companies, fellow CROs, and academic experts, all eager to explore the latest breakthroughs in drug development.

We were excited to share our presentation, “Spray Drying Nanosuspensions: A Novel Approach for Improved Bioavailability in Solid Dosage Forms”, delivered by Anthony James, Executive Director of Business Development. Anthony took the audience on a thorough exploration of the science of spray drying, breaking down how this advanced technique improves solubility and bioavailability, while also helping to accelerate timelines and cut down costs.

The response? Engaged questions, thoughtful discussion, and a clear interest in how spray drying can reshape formulation strategies, especially for challenging small molecules. The presentation sparked valuable connections and collaborative conversations, making it more than just a talk; it became a real exchange of ideas.

Events like this remind us why innovation thrives on collaboration. We're already looking forward to where these conversations will lead next.

A COMMITMENT TO DRUG FORMULATION EXCELLENCE 

There’s something electric about being surrounded by people who are just as passionate about shaping the future of drug development as we are, and that’s exactly what made CPHI 2025 so special. From thought-provoking conversations to exciting new technologies, the event was a powerful reminder of what we can achieve when innovation and collaboration come together.

At Altasciences, we thrive in this kind of environment. With the pharmaceutical world evolving faster than ever, we’re continuously expanding what’s possible, pushing boundaries, exploring cutting-edge methodologies, and enhancing our offerings to meet the demands of modern drug development. And our growing spray drying capabilities are just one exciting example of that, tackling challenges like poor solubility and bioavailability head-on.

Looking back on the energy and ideas exchanged at CPHI, I feel more inspired than ever to keep driving progress. It’s not just about staying ahead of the curve; it’s about helping our clients bring life-changing therapies to the people who need them, faster and more efficiently.

Ready to advance your next project? Get in touch with me or one of my colleagues to see how our innovative solutions can speed up your drug development process. 

ABOUT THE AUTHOR: LISA SANFORD

Lisa Sanford joined Altasciences in 2020 and is currently the Vice President of Business Development. With over 30 years of experience in sales and business development, and nearly two decades in early drug development, Lisa infuses everything she does with extensive industry knowledge, strategic insight, relentless curiosity, and infectious energy.

Beginning her career in sales across a range of industries, from advertising to diagnostics, Lisa found her true calling in life sciences. She has built a reputation for forging strong client relationships, identifying strategic opportunities, and delivering exceptional results. Lisa has also assembled a high-performing, diverse team that embodies her client-first mindset and unwavering belief in the company’s unique value, inspiring others to strive for excellence.

 

_{This blog was originally published in July 2025.}